News

This month marks the centennial of the first case of one of the world's deadliest flu outbreaks, which was reported on a Kansas army base. It is estimated that the 1918 flu infected 500 million people around the world and killed 50-100 million. With the 100^th anniversary, we sat down with graduate student Spencer Fox, who studies the flu virus and flu pandemics.

A discovery that Robert Krug, a University of Texas at Austin molecular biologist, made decades ago has led to the development of a new drug to fight flu infections more effectively than existing drug treatments.

Biologists at The University of Texas at Austin have developed a method for rapidly screening hundreds of thousands of potential drugs for fighting infections, an innovation that holds promise for combating the growing scourge of antibiotic-resistant bacteria. The method involves engineering bacteria to produce and test molecules that are potentially toxic to themselves.

Scientists are developing a set of medical tests called liquid biopsies that can rapidly detect the presence of cancers, infectious diseases and other conditions from only a small blood sample. Researchers at The University of Texas at Austin are developing a new tool for liquid biopsy that could soon provide doctors with a more complete picture of an individual's disease, improving their chances of finding the best treatment, while also sparing patients the pain, inconvenience and long wait times associated with surgical biopsies.

You might expect that the risk of a new flu pandemic — or worldwide disease outbreak — is greatest at the peak of the flu season in winter, when viruses are most abundant and most likely to spread. Instead, all six flu pandemics that have occurred since 1889 emerged in spring and summer months. And that got some University of Texas at Austin scientists wondering, why is that?

​Bryan Davies is an assistant professor in molecular biosciences and biotechnologist at the University of Texas at Austin, leading research into how to combat antibiotic-resistant bacteria and develop new antimicrobials to fight infection.

Microbial biofilms—dense, sticky mats of bacteria that are hard to treat and can lead to dangerous infections—often form in medical equipment, such as flexible plastic tubing used in catheters or in tubes used to help patients breathe. By some estimates, more than 1 million people contract infections from medical devices in U.S. hospitals each year, many of which are due to biofilms. A study from The University of Texas at Austin suggests a possible new way to prevent such biofilms from forming, which would sharply reduce incidents of related hospital-borne infection.

A new model for assessing real-time risk of a Zika virus epidemic in the United States is described in research published in the open access journal BMC Infectious Diseases. The computer simulation, based on data from Texas including population dynamics, historical infection rates, socioeconomics, and mosquito density, is designed to help policymakers gauge the underlying epidemic threat as cases first appear in US cities.

People with cystic fibrosis, diabetes, and chronic obstructive pulmonary disease often develop serious and even life-threatening bacterial infections that are hard to treat, in large part because the bacteria form dense clusters called biofilms. Biofilms are resistant to the host's immune cells and to antibiotics.

A team of engineers and scientists at The University of Texas at Austin is reporting new findings on how the influenza vaccine produces antibodies that protect against disease, research that suggests that the conventional flu vaccine can be improved. The findings were reported in the journal Nature Medicine on Nov. 7.